Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Glow LifeTech (GLOW) has reported additional research on ArtemiC with positive implications for COVID-19 variants
  • The positive findings stem from Phase II clinical and preclinical studies evaluating ArtemiC’s efficacy as an anti-inflammatory agent
  • A further study to support Phase II reinforces that ArtemiC reduces inflammation and suppresses the cytokine storm in patients with COVID-19 variants
  • Glow LifeTech is a biotechnology company focused on producing nutraceutical and cannabinoid-based products
  • Glow LifeTech (GLOW) is up by 5.13 per cent and is currently trading at $0.41 per share

Glow LifeTech (GLOW) has reported additional research on ArtemiC with positive implications for COVID-19 variants.

ArtemiC is a clinically-tested oral spray containing four natural active ingredients: Artemisinin, Curcumin, Boswellia serrata and Vitamin C.

The positive findings stem from Phase II clinical and preclinical studies evaluating ArtemiC’s efficacy as an anti-inflammatory agent to counter increased cytokine production during COVID-19 infections.

Following successful Phase II clinical trials, Glow’s partner for ArtemiC, MGC Pharma, completed additional preclinical animal studies to further support how ArtemiC functions.

The results, announced on May 7, 2021, support that ArtemiC is effective at reducing inflammation and suppressing the cytokine storm believed to be one of the leading causes of mortality with COVID-19 and its variants.

The company holds that once the inflammation tied to COVID-19 is under control, the effects of post-COVID syndrome should be minimized. MGC Pharma will initiate a sub-trial under an upcoming Phase III clinical trial to prove this hypothesis.

ArtemiC is currently under review by Health Canada.

Glow has exclusive rights to market, sell and distribute ArtemiC in Canada, the U.S., Mexico and all Caribbean countries.

The company is not making any express or implied claims that ArtemiC has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

Glow LifeTech is a biotechnology company focused on producing nutraceutical and cannabinoid-based products with dramatically enhanced bioavailability, absorption and effectiveness. 

Glow LifeTech (GLOW) is up by 5.13 per cent and is currently trading at $0.41 per share as of 9:30 am ET.

More From The Market Herald
Rakovina Therapeutics Inc. (TSXV:RKV) - Executive Chairman- Jeffrey Bacha.

" Rakovina (TSXV:RKV) advancing trial programs for cancer treatment

Rakovina Therapeutics (RKV) is advancing its programs for malignant tumour treatment therapies.
MedMira Inc. - CEO, Hermes Chan

" MedMira (TSXV:MIR) gets CE mark during new device regulations

MedMira Inc. (MIR) has received the CE mark for three of seven products submitted this year.
The Market Herald Video

" Empower Clinics (CSE:CBDT) accredited for Covid-19 mobile testing in B.C.

Empower Clinics (CBDT) has received accreditation for its COVID-19 mobile testing solutions.

" Revive (CSE:RVV) gets FDA OK for Bucillamine trials to treat COVID-19

Revive Therapeutics (RVV), a cannabis and psychedelic healthcare company has received feedback from the U.S. FDA to help advance Bucillamine.